Maarten Groeneveld

Title: Maarten Groeneveld: Innovator in Anti-TNF Antibody Production

Introduction

Maarten Groeneveld is a notable inventor based in Oegstgeest, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of methods for producing anti-TNF antibodies. With a total of 3 patents to his name, Groeneveld's work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Groeneveld's latest patents focus on innovative manufacturing methods for producing anti-TNF antibody compositions. One of his inventions relates to methods of manufacture for producing anti-TNF antibodies, specifically a recombinant anti-TNF antibody that includes a heavy chain (HC) with amino acid sequence SEQ ID NO:36 and a light chain (LC) with amino acid sequence SEQ ID NO:37. Another patent presents methods for producing a recombinant anti-TNF antibody with a heavy chain comprising SEQ ID NO:38 and the same light chain, along with compositions that include this recombinant antibody.

Career Highlights

Maarten Groeneveld is currently associated with Janssen Biotech, Inc., where he continues to advance his research in antibody production. His work is crucial in the development of therapies that target tumor necrosis factor (TNF), which plays a significant role in inflammatory processes.

Collaborations

Throughout his career, Groeneveld has collaborated with talented individuals such as Kristopher Barnthouse and Subinay Ganguly. These collaborations have likely contributed to the innovative approaches he has developed in his field.

Conclusion

Maarten Groeneveld's contributions to the field of biotechnology, particularly in the production of anti-TNF antibodies, highlight his role as an influential inventor. His patents and ongoing work at Janssen Biotech, Inc. demonstrate his commitment to advancing medical science and improving therapeutic options for patients.